Prostate Cancer

The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.

In response to the drug’s developer, the FDA added overall survival and other end point data to the label of darolutamide for its indication for treating patients with nonmetastatic castration-resistant prostate cancer who are receiving standard androgen-deprivation therapy.

“These findings highlight the dynamic interplay between both providers and their patients as well as between the latter’s [health literacy] and [shared decision making] that should inform the creation and promulgation of [shared decision making] guidelines, specifically when considering patients with low [health literacy],” wrote David-Dan Nguyen, MPH, and colleagues.

Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.

Treatment with olaparib versus physician’s choice of standard therapy led to a significantly longer duration of overall survival in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1/2 or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

Declan Murphy, MB, BCh, shares his thoughts on the potential for prostate-specific membrane antigen PET/CT to impact outcomes for patients with localized and high-risk prostate cancers.

Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.

“In the long-term, active surveillance is a safe and viable option for men with low-risk and carefully selected intermediate-risk prostate cancer,” the study authors wrote.

Though these collective findings demonstrate that genetic predisposition to increased weight is protective against breast and prostate cancer, further research is still necessary to work out exactly how this protection is provided, especially in breast cancer.

The expert in urologic oncology spoke about the advancements made in 2020, as well as areas of prostate cancer care which he believes remain to be improved.

Relugolix (Orgovyx) is the first oral drug in its class to receive FDA approval for the treatment of adults with advanced prostate cancer.

Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.

Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

A clear and reliable biomarker to select patients with prostate cancer for active surveillance or focal therapy has not yet been determined but inferring a course of action from existing biomarkers may be possible.

The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.

Research shows that the PARP inhibitor demonstrated superior PFS and OS for patients with metastatic castration-resistant prostate cancer with BRCA1, BRCA2, or ATM alterations.

An update on the PROSPER trial analyzing enzalutamide plus androgen deprivation therapy found a lower risk of death than placebo for patients with non-metastatic CRPC.

Deep-learning algorithms could be used to alert pathologists to suspicious areas of cancer burden prior to clinical assessment, according to Nitin K. Yerram, MD.

The novel androgen receptor-signaling inhibitor led to negative repeat biopsies after 90 days of treatment among men with very-low risk to favorable intermediate risk prostate cancer on active surveillance.

Enzalutamide improved progression-free survival and increased time to prostate-specific antigen progression, compared with bicalutamide, in patients with nonmetastatic castration-resistant prostate cancer.

The agency approved the first PSMA-targeted PET imaging drug to treat men with prostate cancer.

According to researchers, these immuno-oncologic differences may aid in developing a genomically adaptive approach to treating prostate cancer in this patient population.

This trial is the first randomized trial of men with recurring prostate cancer to show that treatment based on advanced molecular imaging can improve disease-free survival rates.

According to the researchers, the high-quality evidence observed thus far supports the endorsement of this scoring system as a new staging system for prostate cancer.

Researchers suggested that platinum-based treatment may be considered an option in a biomarker-positive population of patients with advanced prostate cancer with DNA repair gene aberrations.

The FDA has approved the FoundationOne Liquid CDx to identify patients with BRCA1, BRCA2, and/or ATM alterations in patients with metastatic castration-resistant prostate cancer who may be appropriate for treatment with olaparib.

In a mock tumor board on prostate cancer on Twitter, health care providers came together to discuss real patient cases and present various treatment options for review.

A study presented at the ASTRO Annual Meeting found that adding the advanced PET radiotracer fluciclovine (Axumin) to conventional imaging for patients with recurrent prostate cancer may improve disease-free survival rates.

The FDA has lifted the clinical hold on the phase 1 study of P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.